Black Diamond Therapeutics (BDTX) AI Stock Analysis

• Market Cap: $156.57M
• Dividend Yield: N/A
• Average Volume (3M): 833.93K
• Price to Earnings (P/E): 11.6
• Beta (1Y): 2.24
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 56,935,280
• 10 Day Avg. Volume: 673,257
• 30 Day Avg. Volume: 833,934
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.12
• Enterprise Value/Revenue: 0.27
• Enterprise Value/Gross Profit: 0.27
• Enterprise Value/Ebitda: 3.79
• 1Y Price Target: $10.50
• Price Target Upside: 275.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 33 Underperform
• Price Target: ―

Black Diamond Therapeutics is currently a high-risk investment due to its weak financial performance characterized by zero revenue and negative cash flow. The technical analysis suggests continued volatility, and the valuation highlights typical challenges of early-stage biotech firms. However, the recent strategic partnership with Servier offers potential long-term benefits. The overall score reflects the significant financial challenges and current market sentiment, with potential upside from successful execution of its strategic initiatives.

Positive Factors

Cash Position

Black Diamond ended 2Q25 with approximately $143M in cash, cash equivalents, and marketable securities.

Clinical Trial Results

Initial safety and efficacy results from the Ph. II trial of BDTX-1535 in NSCLC patients are considered encouraging and competitive with alternative non-targeted therapies.

Financial Performance

Black Diamond reported a net loss of $0.19 per share, which was better than the prior estimated net loss of $0.33 per share.

Negative Factors

Competitive Landscape

The evolving competitive landscape in 2L NSCLC presents challenges and a modest commercial opportunity.

Product Launch Delay

The initial U.S. launch of silevertinib (BDTX-1535) has been moved to 2028 from the prior 2026.

Black Diamond Therapeutics Business Overview & Revenue Model

Company Description

Black Diamond Therapeutics (BDTX) is a biotechnology company dedicated to the discovery and development of precision medicines for genetically defined cancers. The company focuses on creating innovative therapies that target oncogenic mutations, including previously undruggable mutations, using its proprietary Mutation-Allostery-Pharmacology (MAP) platform. Black Diamond Therapeutics is at the forefront of cancer treatment innovation, aiming to provide more effective and personalized treatment options for patients.

How the Company Makes Money

Black Diamond Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products targeting specific mutations in cancer treatment. The company generates revenue by advancing its proprietary drug candidates through clinical trials, seeking regulatory approval, and ultimately bringing these therapies to market. Significant revenue streams may include sales of approved drugs, partnerships, and collaborations with larger pharmaceutical companies for co-development and commercialization efforts. Additionally, the company may receive milestone payments and royalties from licensing agreements, providing a diversified approach to revenue generation. However, as a biotechnology company in the clinical development stage, Black Diamond Therapeutics may also rely on funding from investors and financial markets until its products are commercially available.

Black Diamond Therapeutics Financial Statement Overview

Summary

Black Diamond Therapeutics is facing significant financial challenges, characterized by zero revenue generation, negative equity, and persistent negative cash flows. The company may depend heavily on financing activities to sustain operations, which poses a high-risk profile typical for early-stage biotechnology firms.

Income Statement

The company has consistently reported zero revenue over the years, indicating a lack of commercialized products or services. This results in gross profit and net income being highly negative. The EBIT and EBITDA margins are unavailable due to zero revenue, and the overall income statement shows a persistent negative net income trend.

Balance Sheet

The balance sheet reveals a challenging financial position with negative stockholders' equity for multiple years, indicating financial instability. The debt-to-equity ratio is not applicable due to negative equity, and the company has high liabilities relative to its assets. The equity ratio is also negative, underscoring the precarious financial health.

Cash Flow

Operating cash flow is consistently negative, reflecting ongoing cash burn without revenue generation. While there is some positive movement in investing and financing cash flows, the free cash flow remains negative with no growth, suggesting a reliance on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	70.52M	0.00	0.00	0.00	0.00	0.00
Gross Profit	70.09M	-343.00K	-437.00K	-3.24M	-2.22M	-600.00K
EBITDA	4.96M	-69.33M	-86.02M	-92.32M	-126.67M	-66.65M
Net Income	14.44M	-69.68M	-82.44M	-91.17M	-125.60M	-67.25M
Balance Sheet
Total Assets	166.38M	122.64M	158.57M	156.25M	247.68M	329.67M
Cash, Cash Equivalents and Short-Term Investments	29.99M	98.58M	131.40M	122.81M	209.79M	315.07M
Total Debt	16.97M	22.19M	25.30M	28.14M	28.46M	8.74M
Total Liabilities	33.77M	39.35M	41.83M	40.56M	491.50M	21.91M
Stockholders Equity	132.61M	83.28M	116.74M	115.69M	195.90M	307.76M
Cash Flow
Free Cash Flow	17.87M	-62.30M	-66.75M	-85.27M	-102.86M	-52.29M
Operating Cash Flow	17.87M	-62.30M	-66.72M	-85.08M	-100.15M	-52.15M
Investing Cash Flow	-20.64M	16.97M	16.35M	53.37M	130.61M	-281.69M
Financing Cash Flow	-45.00K	25.55M	71.93M	177.00K	729.00K	214.94M

Black Diamond Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDTX, the sentiment is Positive. The current price of 2.8 is above the 20-day moving average (MA) of 2.70, above the 50-day MA of 2.74, and above the 200-day MA of 2.26, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 52.14 is Neutral, neither overbought nor oversold. The STOCH value of 49.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BDTX.

Black Diamond Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VYGR	54 Neutral	$186.38M	5.05	-37.26%	―	-70.38%	-683.06%
Sector *	51 Neutral	$7.86B	-0.33	-41.57%	2.23%	23.26%	-2.03%
SLS	43 Neutral	$202.17M	―	-180.71%	―	―	64.43%
DMAC	42 Neutral	$295.14M	―	-73.41%	―	―	-31.78%
GALT	35 Underperform	$274.18M	―	48.74%	―	―	17.80%
TIL	34 Underperform	$182.27M	―	-51.74%	―	―	29.72%
BDTX	33 Underperform	$156.57M	11.61	11.85%	―	―	―

Black Diamond Therapeutics Corporate Events

Black Diamond Therapeutics Partners with Servier for BDTX-4933

On March 18, 2025, Black Diamond Therapeutics entered into a License Agreement with Servier Pharmaceuticals, granting Servier a worldwide license to develop and commercialize BDTX-4933, a small molecule targeting RAF/RAS-mutant solid tumors. This agreement includes an upfront payment of $70 million to Black Diamond and potential milestone payments up to $710 million, along with royalties. Servier will lead the development and commercialization of BDTX-4933, which is currently in Phase 1 trials, with applications in non-small cell lung cancer and other solid tumors. This strategic partnership aims to address unmet medical needs in oncology and enhance Black Diamond’s position in the industry.